Breast cancer stage at diagnosis, patient age and molecular tumor subtype influence disease progression. The aim of this study was to analyze the relationships between these factors and survival in breast cancer patients among the Italian population using data from the AIRTUM national database. We enrolled women with primary breast cancer from 17 population‐based cancer registries. Patients were subdivided into older (>69 years), middle (50–69 years) and younger age groups (<50 years) and their primary tumors categorized into four molecular subtypes based on hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. There were 8831 patients diagnosed between 2010 and 2012 included. The most represented age group was 50– 69 years (41.7%). In 5735 cases the molecular subtype was identified: HER2–/HR+ was the most frequent (66.2%) and HER2+/HR− the least (6.2%). Of the 390 women with metastases at diagnosis, 38% had simultaneous involvement of multiple sites, independent of age and molecular profile. In women with a single metastatic site, bone (20% of cases), liver (11%), lung (7%) and brain (3%) were the most frequent. In the studied age groups with different receptor expression profiles, the tumor metastasized to target organs with differing frequencies, affecting survival. Five‐year survival was lowest in women with triple‐negative (HER2−/HR–) tumors and women with brain metastases at diagnosis.
Molecular subtypes, metastatic pattern and patient age in breast cancer: An analysis of italian network of cancer registries (airtum) data / Tagliabue, G.; Fabiano, S.; Contiero, P.; Barigelletti, G.; Castelli, M.; Mazzoleni, G.; Boschetti, L.; Fanetti, A. C.; Puppo, A.; Musolino, A.; Cirilli, C.; Seghini, P.; Mangone, L.; Caldarella, A.; Lotti, F.; Mazzucco, W.; Benedetto, A.; Dinaro, Y. M.; Sferrazza, A.; Pinna, P.; Perotti, V.. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 10:24(2021), p. 5873.5873. [10.3390/jcm10245873]
|Appare nelle tipologie:||1.1 Articolo su rivista|